J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
July 14, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, JULY 14, 2025
J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers

Coronavirus chronicle

Reuters
23 September, 2020, 04:50 pm
Last modified: 23 September, 2020, 04:57 pm

Related News

  • US limits use of J&J's Covid vaccine on blood clot risks
  • J&J says its single dose protects against breakthrough Covid-19 for up to 6 months
  • J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
  • EU regulator backs J&J Covid-19 booster dose for adults
  • Healthcare giant Johnson & Johnson to split into two companies

J&J kicks off final study of single-shot Covid-19 vaccine in 60,000 volunteers

Rival vaccines from Moderna Inc, Pfizer Inc and AstraZeneca all require two shots separated by several weeks, which make them much more difficult to administer

Reuters
23 September, 2020, 04:50 pm
Last modified: 23 September, 2020, 04:57 pm
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo

Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot Covid-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses.

The company expects results of the Phase III trial by year end or early next year, Dr Paul Stoffels, J&J's chief scientific officer, said in a joint press conference with officials from the National Institutes of Health and the Trump administration.

Rival vaccines from Moderna Inc, Pfizer Inc and AstraZeneca all require two shots separated by several weeks, which make them much more difficult to administer.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"The benefits of a single-shot vaccine are potentially profound in terms of mass immunization campaigns and global pandemic control," Dr Dan Barouch, a Harvard vaccine researcher who helped design J&J's Covid-19 vaccine, said in a telephone interview.

Stoffels said J&J would publish a detailed study protocol for its phase 3 trial Wednesday on the company's website, joining the three other vaccine makers that have made these study plans available in recent weeks after calls for increased transparency in the trials.

Stoffels said J&J started the phase 3 trial after seeing positive results in its phase 1/2 trial in the United States and Belgium. The company plans to release those results imminently.

Stoffels said the safety and level of protection in the study were on par with what was seen in the company's animal studies, and said the results showed a single dose could offer sufficient protection "for a long time."

J&J's late-stage trial will use as many as 215 sites in the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. The company plans to manufacture as many as 1 billion doses in 2021, and more after that, Stoffels said.

The goal of the trial is to test whether the vaccine can prevent moderate to severe Covid-19 after a single dose, but it will also look to see if the vaccine can prevent serious disease requiring medical intervention and whether it can prevent milder cases of the virus.

Stoffels predicts it will take six weeks to two months to enroll the trial, and said the company hopes to get an answer on whether the vaccine works "around the end of the year or early next year."

It is not clear how fast the company could get regulatory approval, but J&J plans to manufacture doses before approval, so it could start distribution quickly.

The trial will be overseen by an independent Data and Safety Monitoring Board (DSMB) that will review vaccine safety and effectiveness. In the press conference, Dr Francis Collins, director of the National Institutes of Health, said all three of the vaccines being organized and supported by the federal government's Operation Warp Speed - J&J's, Moderna's and AstraZeneca's - share a common DSMB. Pfizer is running its own trial and has a separate DSMB, Collins said.

J&J's trial is designed to test for a vaccine that is 60 percenteffective. In the study protocol, that could be determined after 154 people became infected with the virus. Stoffels said the company will start counting cases of Covid-19 infections within the study population 15 days after individuals are vaccinated.

The DSMB will take its first look at the vaccine's efficacy after 20 people have become infected.

Collins said the DSMB does not include any federal employees and is made up of "very highly experienced" scientists and statistical experts.

"Until they are convinced that there's something there that looks promising, nothing is unblinded and sent to the FDA. So everybody should feel pretty reassured," Collins said. His comments follow concerns government scientists may be pressured to rush the vaccine testing process to boost US President Donald Trump's re-election bid. 

J&J Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image. Photo: Collected
    Dollar gains Tk1.8 as BB buys at higher rates, lifting market floor
  • US President Donald Trump speaks to the press as he arrives at the White House in Washington, DC, US, July 13, 2025. REUTERS/Annabelle Gordon
    Trump threatens 'very severe' tariffs against Russia if no Ukraine peace deal within 50 days
  • Sanjida Ahmed Tonni, along with hundreds of other students, was attacked by Chhatra League thugs on 15 July 2024. Photo: Rohet Ali Rajib
    Women of the July Uprising: She stood in courage, left in silence

MOST VIEWED

  • Graphics: TBS
    Bangladesh Bank buys $171m at higher rate in first-ever auction
  • From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
    From Gulf to Southeast Asia, why Bangladeshis are facing visa denials
  • Infographic: TBS
    Dollar price plummets by Tk2.9 in a week as demand wanes
  • Energy Adviser Fouzul Kabir Khan speaking about tariff negotiations with United States on 13 July 2025. Photo: TBS
    US wants a framework agreement with Bangladesh that includes their security concerns: Fouzul
  • CNG drivers blockaded a road in Banani demanding route allocation on 13 July 2025. Photo: TBS
    CNG drivers block road in Banani for hours, causing Mohakhali-Uttara gridlock 
  • Representational image. Photo: Mohammad Minhaj Uddin/TBS
    Navy-run Dry Dock takeover boosts Ctg Port container handling, daily avg up 7%

Related News

  • US limits use of J&J's Covid vaccine on blood clot risks
  • J&J says its single dose protects against breakthrough Covid-19 for up to 6 months
  • J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
  • EU regulator backs J&J Covid-19 booster dose for adults
  • Healthcare giant Johnson & Johnson to split into two companies

Features

DU students at TSC around 12:45am on 15 July 2024, protesting Sheikh Hasina’s insulting remark. Photo: TBS

‘Razakar’: The butterfly effect of a word

8h | Panorama
Photo: Collected

Grooming gadgets: Where sleek tools meet effortless styles

1d | Brands
The 2020 Harrier's Porsche Cayenne coupe-like rear roofline, integrated LED lighting with the Modellista special bodykit all around, and a swanky front grille scream OEM Plus for the sophisticated enthusiast looking for a bigger family car that isn’t boring. PHOTO: Ahbaar Mohammad

2020 Toyota Harrier Hybrid: The Japanese Macan

2d | Wheels
The showroom was launched through a lavish event held there, and in attendance were DHS Motors’ Managing Director Nafees Khundker, CEO Imran Zaman Khan, and GMs Arman Rashid and Farhan Samad. PHOTO: Akif Hamid

GAC inaugurate flagship showroom in Dhaka

2d | Wheels

More Videos from TBS

Will Patriot missile defense save Ukraine?

Will Patriot missile defense save Ukraine?

1h | Others
Market intermediaries want changes in policies

Market intermediaries want changes in policies

2h | TBS Today
Robbery 'in front' of the police, what happened next...

Robbery 'in front' of the police, what happened next...

2h | TBS Stories
Conspirators want Bangladesh not to hold elections: Fakhrul

Conspirators want Bangladesh not to hold elections: Fakhrul

2h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net